| Name | Title | Contact Details |
|---|
Cognition Therapeutics Inc. is a drug discovery and development company located in Pittsburgh, Pennsylvania. Founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.
United Home Care Services, Inc. is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Due to its expertise in TPD, Plexium has entered into strategic collaborations with Amgen and AbbVie to discover and develop a wide range of new therapies from cancer to neurological diseases. Supported by high quality investors, Plexium is well positioned to transform medicine.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.
Medicilon Inc. is a prominent Contract Research Organization (CRO) based in Shanghai, China, established in 2004. The company specializes in comprehensive preclinical drug discovery and development services, helping pharmaceutical and biotech clients progress from concept to Investigational New Drug (IND) filing. With over 300,000 square feet of lab space and a team of more than 2,400 scientists, Medicilon is recognized for its expertise and innovation in the field. The company offers a wide range of services, including drug discovery, CMC development, and preclinical research. Their capabilities encompass precision chemical synthesis, GMP-compliant API manufacturing, and extensive pharmacology and toxicology studies. Medicilon adheres to FDA methodologies and international standards, ensuring regulatory compliance throughout the development process. With a focus on client-centric solutions, Medicilon has successfully conducted over 10,000 studies and serves more than 2,000 clients worldwide, emphasizing long-term partnerships and support for drug development programs.